---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-26-000011"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:37:24.685426+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quanterix Q4 revenue $43.9M (+25% YoY); guides 2026 rev $169-174M, cash flow breakeven H2

## Summary
- Q4 revenue $43.9M vs $35.2M prior year (+25%); full-year revenue $138.9M (+1% YoY).
- GAAP gross margin 45.7% (Q4) and 46.8% (FY); adjusted gross margin 50.0% (Q4) and 47.3% (FY).
- Adjusted EBITDA loss of $7.9M in Q4 and $44.9M for FY; cash balance $121.6M.
- Initial 2026 guidance: revenue $169-174M, adjusted gross margin 49-53%, cash ~$100M year-end.
- Filed 510(k) for Alzheimer's blood test; CMS set reimbursement rate of $897 for LucentAD Complete.

## SEC filing metadata
- accession: 0001503274-26-000011
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/0001503274-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327426000011/qtrx-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-26-000011
- JSON: https://secwatch.observer/filing/0001503274-26-000011.json
- Plain text: https://secwatch.observer/filing/0001503274-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.